No Data
Jianyin International: Maintains the "Buy" rating for MAOYAN ENT (01896), with the Target Price raised to HKD 9.2.
Jianyin International believes that Maoyan can benefit from the recovery of the Industry this year.
[Brokerage Focus] Jianyin International maintains a "Outperform" rating for MAOYAN ENT (01896), expecting it to experience a turnaround in the fiscal year 2025.
Jinwu Financial News | Jianyin International has released a Research Report, predicting that MAOYAN ENT (01896) will perform poorly in the 2024 fiscal year due to adverse Industry winds. The total revenue for the 2024 fiscal year is expected to decline by 12% year-on-year to 4.2 billion yuan, which is 3% lower than market expectations. Although the China Film Co., Ltd. industry saw a 22% year-on-year decrease in box office revenue, MAOYAN ENT's online ticketing revenue is anticipated to be 1.95 billion yuan, down 14% year-on-year, benefiting from steady growth in entertainment event ticketing, resulting in a smaller decline than the Industry. Due to poor box office performance of some key projects, with some even incurring losses, the revenue from entertainment content is expected to be 2.05 billion yuan, year-on-year down.
With blockbuster hits like "The Investiture of the Gods Part II" and "Nezha: The Devil Child of Miracle" arriving, is the film and television Sector welcoming the explosive opportunity of the "Spring Festival period"?
With the orderly supply of high-quality film content, from beta to alpha, the long-term value of producers of quality content remains unchanged.
Morgan Stanley: It is expected that this year's Spring Festival box office in China will likely set a new historical high.
Morgan Stanley predicts that the box office for the Spring Festival period will be 8.8 billion yuan, a year-on-year increase of 9%.
Hong Kong stock Concept tracking | High-quality films will increase supply, and the movie market is expected to continue to warm up in 2025 (including Concept stocks).
Morgan Stanley: The box office for the Chinese New Year period in 2025 is expected to set a new historical record.
[Brokerage Focus] Tianfeng maintains a "Buy" rating on MAOYAN ENT (01896), expecting that the online movie ticketing business may face short-term pressure due to Large Cap influences.
Jinwu Finance News | Tianfeng issued a Research Report indicating that MAOYAN ENT (01896) released "2024 China Film Market Data Insights." In 2024, China's total box office revenue is expected to reach 42.502 billion, a year-on-year decline of 23%. The overall market supply has not yet recovered to pre-pandemic levels. In 2024, the bank expects the company's online entertainment ticketing business to generate revenue of 1.94 billion yuan, a year-on-year decline of 14.2%, with a drop less than the Large Cap, mainly due to the contribution of performance elasticity from offline performance business. The bank believes that the online movie ticketing business may face short-term pressure due to the impact of the Large Cap, while the supply and demand in the offline performance market are strong, and activity levels are increasing.
Should Weakness in Maoyan Entertainment's (HKG:1896) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
